Biosimilar-to-Biosimilar Switching: The Complete IP, Clinical, and Market Playbook For pharma IP teams, portfolio managers, R&D leads, and institutional investors […]
The 55% figure should stop every pharma IP team in its tracks. That is the share of new small-molecule drugs
Generic drug development has never been a solo endeavor, but the industry has spent the last decade pretending otherwise. Companies
Generic Drug Partnerships: The Definitive IP and Deal Structure Playbook for ANDA Filers Read Post »
The average generic drug program takes 3 to 4 years from target identification to FDA approval. For most companies, that
Generic Drug Development Timelines: The Definitive Playbook for Faster ANDA Approval Read Post »
Strategic Patent Barriers and Market Exclusivity in the Pharmaceutical Industry Pharmaceutical companies use patent portfolios to prevent generic and biosimilar
Using Drug Patents to Block Competitors: The Tactics and Consequences Read Post »
How AI, blockchain, multi-sourcing, and smarter policy can cut costs, eliminate fragility, and keep patients supplied Generic drugs fill 89%
Fix Your Generic Drug Supply Chain Before a Shortage Does It for You Read Post »
A technical deep dive for pharma IP teams, R&D leads, and institutional investors Master Key Takeaways A drug’s market monopoly
For pharma IP teams, portfolio managers, R&D leads, and institutional investors who need more than headline growth figures. Executive Summary
Latin America Specialty Generics: The Complete IP, Regulatory & Market Entry Playbook Read Post »
A patent does not generate revenue. A masterfully executed commercial strategy does. This guide breaks down exactly how pharmaceutical companies,
Sign in or create a free account to read this DrugPatentWatch article
